A recent study published in Diabetes Technology & Therapeutics (DTT) has confirmed the accuracy and safety of the Dexcom G7 continuous glucose monitor (CGM) for adults with diabetes. The device, designed for 15.5-day use, achieved the lowest mean absolute relative difference (MARD) recorded under U.S. FDA criteria, marking a significant advancement in glucose monitoring technology.

The study involved 130 adults with type 1 or type 2 diabetes across six U.S. centers. Participants used the Dexcom G7 CGM for 15 days, generating 20,310 matched pairs of CGM and venous blood glucose measurements. The results showed a MARD of just 8.0%, surpassing performance goals for integrated CGMs (iCGMs).

Dr. Satish Garg, lead author and Editor-in-Chief of DTT, highlighted the device’s success, stating, “The device exceeded iCGM performance goals, and user experiences were broadly positive.” No serious adverse events were reported, underscoring the G7’s safety profile. The study also noted a rapid 27-minute warm-up time, enhancing practicality for users.

The Dexcom G7 CGM’s high accuracy and extended wear time offer a reliable tool for diabetes management, potentially improving patient outcomes. Future research may explore its long-term benefits across diverse populations.